Alaunos Therapeutics Inc. stocks have been trading up by 30.28 percent amid heightened optimism over its latest oncology pipeline developments.
Click Here for a Millionaire's POV on Trading TCRT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Alaunos Therapeutics completed the Velaris Therapeutics acquisition, adding ActRII‑Fc ligand traps and biologics for pulmonary arterial hypertension and related cardiopulmonary diseases.
- The company raised about $350M in a concurrent private placement of Series C non‑voting convertible preferred stock, funding operations into 2029.
- New capital is expected to push multiple Velaris‑derived candidates through proof‑of‑concept and early regulatory filings.
- On the news, TCRT shares jumped about 126% as traders rushed in.
- Another report showed TCRT up roughly 225% on extremely heavy volume after the Velaris deal and $350M raise.
Live Update At 08:32:30 EDT: On Friday, October 16, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 30.28%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TCRT has gone from sleepy micro‑cap to full‑blown momentum story in a few sessions. The daily chart shows Alaunos Therapeutics trading under $1 for weeks, then ripping from $0.78 on 2026/10/09 to an intraday high above $4 on 2026/10/14 after the Velaris Therapeutics acquisition and $350M private placement headlines hit. Even after pullbacks, TCRT closed at $2.18 on 2026/10/15, still more than double its pre‑news levels.
Financially, Alaunos Therapeutics is early‑stage and burning cash. Quarterly revenue is only about $5,000, with a price‑to‑sales ratio near 957 — pure story stock territory. The latest report shows a quarterly net loss of about $952,000 and negative operating cash flow of roughly $300,000. TCRT’s current ratio sits around 0.8 and working capital is negative, which, without new capital, would scream balance‑sheet stress.
More Breaking News
- SNAP Stock Rallies As SPECS AR And Activist Pressure Collide
- Opendoor Stock Holds Key Support As Wall Street Resets Expectations
- ETSY Stock Rallies As Upgrades And Payoneer Deal Boost Bulls
- TCRT Stock Explodes As Alaunos Seals Velaris Deal And $350M Raise
That is why traders are locked on the new $350M war chest. For a company with just $124,000 in cash and about $1.5M in total assets, this is a complete reset of the TCRT balance sheet and runway. The fundamentals still show risk, but now the clock has been dramatically extended.
Why Traders Are Watching TCRT After The Velaris Deal
The Velaris Therapeutics acquisition is a pivot moment for TCRT. Alaunos Therapeutics was already a speculative biotech name; with Velaris, it turns into a broader cardiopulmonary disease platform story. The acquired pipeline of ActRII‑Fc ligand traps and biologics targets pulmonary arterial hypertension and related cardiopulmonary diseases — areas where any solid clinical data can move a stock fast.
For traders, the key is not just the science. It is the pairing of that science with serious funding. TCRT locked in about $350M via a private placement of Series C non‑voting convertible preferred stock. Management expects this to fund operations into 2029 and push multiple Velaris‑derived candidates through proof‑of‑concept and early regulatory filings. In plain English: multiple shots on goal, with years of cash to take them.
The market reaction shows how dramatic this shift is. One report pegs the TCRT move at about 126% after the deal and financing news. Another has Alaunos Therapeutics up roughly 225% on extremely heavy volume. That kind of range tells you exactly what’s happening — traders piling in, algos chasing, shorts scrambling, and late buyers getting whipped around.
Intraday, TCRT now trades like a classic momentum runner. The 5‑minute chart shows fast swings between $2.70 and just over $3 in premarket action, with constant back‑and‑forth around the $2.80–$2.90 zone. That tells short‑term traders two things: liquidity is finally here, and the crowd is paying attention. With a tiny historical revenue base and a massive new cash pile, Alaunos Therapeutics is trading almost entirely on narrative, catalysts, and the tape.
Conclusion
Alaunos Therapeutics has given traders exactly what they look for in a high‑beta biotech: a clear catalyst, a transformed balance sheet, and violent price action. TCRT’s Velaris acquisition brings in a new cardiopulmonary pipeline, including VLR199 for pulmonary arterial hypertension, while the $350M private placement removes near‑term funding fear and extends the cash runway out to 2029. That combination explains why the stock has surged more than 100%–200% on huge volume.
But the same traits that make TCRT exciting also raise the risk. Alaunos Therapeutics is still deeply unprofitable, with minimal revenue and heavy losses. The preferred stock financing adds a layer of dilution and conversion dynamics traders need to respect. Every future headline — early data, trial delays, regulatory steps — can send TCRT sharply higher or lower.
This is where discipline matters. The move in TCRT fits what active traders see again and again in small‑cap biotech: a catalyst lights the match, funding pours gasoline on it, and the chart does the rest. As Tim Sykes likes to tell his community, “Volatility is opportunity for prepared traders, but only if you respect risk and cut losses quickly.” That emphasis on risk aligns closely with the view of many veteran day traders; as Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.”. For anyone studying TCRT now, the focus should be on the catalysts ahead, the levels on the chart, and a clear trading plan — not hope. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.